Adjusted net profit is expected to grow 120. EBITDA margins are expected to improve 635 bps YoY to 23% mainly due to marketing, travel expenses and a better product mix. Sun Pharma India specializes in technically complex products, offering a comprehensive therapy basket, and owns 29 brands out of the top 300 pharmaceutical brands in India.

Taro's sales are expected to decline 22% YoY on constant currency basis amid high base effect and continued pressure on dermatology portfolio. Sun Pharma’s branded generics business in India commands leading position in high-growth chronic therapies and strong positioning in the acute segment. US is expected to grow ~2.2% YoY to Rs 2773 crore amid continued traction in speciality portfolio. Revenues are likely to grow 7% YoY to | 8760 crore led by 10% growth in domestic and 12% growth in both RoW and Emerging Markets. Company reported net profit after tax of Rs 1918.11 Crore in latest quarter. sun pharma sharesun pharma share news sun pharma share latest newssun pharma share news todaysun pharma share price sun pharma share analysissun pharma share. The share price of any stocks is volatile and keeps changing throughout the day owing to different factors. Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 149238.64 Crore) operating in Pharmaceuticals sector.įor the quarter ended 31-12-2020, the company reported a Consolidated Total Income of Rs 9151.73 Crore, up 3.89 % from last quarter Total Income of Rs 8808.91 Crore and up 10.60 % from last year same quarter Total Income of Rs 8274.73 Crore. What is the Share Price of Sun Pharma Inds. The current market price of Sun Pharmaceutical Industries Ltd. ICICI Direct has buy call on Sun Pharma with a target price of Rs 675.

Sun pharma moneycontrol